For instance, MRX-2843, a selective MERTK-inhibitor, has proven effective in MERTK-negative acute lymphoblastic leukemia (ALL) and NSCLC in immunocompetent models, suggesting immune-mediated therapeutic activity, which was granted an early phase of clinical trials in patients (e.g., NCT04872478, NCT04762199) [101]. This evidence concerns the gene MERTK and acute lymphoblastic leukemia.